The Overview
Enliven Therapeutics announced FDA alignment on the final design of its ENABLE-2 pivotal Phase 3 trial for relcobatinib (ELVN-001) in patients with previously treated chronic myeloid leukemia (CML). The randomized, 2L+ trial is expected to enroll approximately 450 adults, comparing relcobatinib 80 mg once daily against investigator-selected second-generation TKIs (dasatinib, nilotinib, or bosutinib). The primary endpoint is major molecular response (MMR) at Week 24, with a key secondary endpoint of MMR at Week 96. The trial is designed to demonstrate statistical superiority with at least a 10 percentage point improvement in MMR rate over the control arm, which Enliven believes represents a clinically meaningful improvement. The company remains on track to initiate ENABLE-2 before year-end 2026.
Knolens Analysis
At a Glance
| Indication | Chronic myeloid leukemia |
| Drug | relcobatinib |
| Mechanism of Action | BCR::ABL1 kinase inhibitor |
| Company | Enliven Therapeutics, Inc. |
| Trial Phase | Phase 3 |
| Trial Acronym | ENABLE-2 |
| Category | Clinical Trial Event |
| Sub Category | Trial Initiation / First Patient In (FPI) |
| Therapeutic Area | Hematology |
| Regulatory Agency | U.S. Food and Drug Administration (FDA) |
| Trial Initiation Timeline | before year-end 2026 |
| Patient Population | adults with CML previously treated with one or more tyrosine kinase inhibitors (TKIs) |
| Number of Patients | approximately 450 |
| Dosage | 80 mg once daily |
| Comparator Arm | investigator-selected second-generation TKI (dasatinib, nilotinib, or bosutinib) |
| Primary Endpoint | major molecular response (MMR) at Week 24 |
| Key Secondary Endpoint | MMR at Week 96 |
| Statistical Superiority Threshold | at least 10 percentage points over the control arm |
| Target | BCR::ABL1 gene fusion |
| Line of Therapy | 2L+ |
Enliven Secures FDA Alignment for Relcobatinib Phase 3 CML Trial
Enliven Therapeutics announced FDA alignment on the final design of its ENABLE-2 pivotal Phase 3 trial for relcobatinib (ELVN-001) in patients with previously treated chronic myeloid leukemia (CML). The randomized, 2L+ trial is expected to enroll approximately 450 adults, comparing relcobatinib 80 mg once daily against investigator-selected second-generation TKIs (dasatinib, nilotinib, or bosutinib). The primary endpoint is major molecular response (MMR) at Week 24, with a key secondary endpoint of MMR at Week 96. The trial is designed to demonstrate statistical superiority with at least a 10 percentage point improvement in MMR rate over the control arm, which Enliven believes represents a clinically meaningful improvement. The company remains on track to initiate ENABLE-2 before year-end 2026.
- The ENABLE-2 trial is a planned randomized, 2L+ Phase 3 study targeting approximately 450 adult patients with chronic myeloid leukemia who have been previously treated with one or more tyrosine kinase inhibitors. Participants will be randomized 1:1 to receive either relcobatinib 80 mg once daily or an investigator-selected second-generation TKI, including dasatinib, nilotinib, or bosutinib. This design aims to directly compare relcobatinib's efficacy and safety against established treatments in a relevant patient group.
- The primary endpoint for the ENABLE-2 trial is major molecular response (MMR) at Week 24, a critical measure of treatment efficacy in CML. A key secondary endpoint will assess MMR at Week 96. The trial is statistically powered to demonstrate superiority, requiring an improvement in MMR rate of at least 10 percentage points over the control arm. Enliven believes this difference would signify a clinically meaningful advancement over currently available second-generation TKIs.
- Enliven Therapeutics has successfully reached alignment with the U.S. Food and Drug Administration (FDA) on the comprehensive design of the ENABLE-2 pivotal Phase 3 trial. This regulatory milestone provides a clear and validated pathway for the trial's progression. The company has reiterated its commitment to initiating the ENABLE-2 trial before the end of 2026, underscoring its focused development strategy for relcobatinib.
Frequently Asked Questions
How fast does chronic myeloid leukemia progress?
Chronic myeloid leukemia (CML) typically progresses slowly through distinct phases: chronic, accelerated, and blast crisis. The chronic phase, often lasting 3-5 years or more without treatment, is characterized by mild symptoms or an asymptomatic presentation. Without effective therapy, the disease can evolve to an accelerated phase, marked by increasing blast counts and worsening symptoms, eventually leading to a highly aggressive blast crisis resembling acute leukemia. Tyrosine kinase inhibitors (TKIs) have profoundly altered this natural history, often preventing progression beyond the chronic phase.
What is the survival rate for patients with chronic myeloid leukemia (CML)?
The 5-year survival rate for patients with chronic myeloid leukemia (CML) has dramatically improved with the advent of tyrosine kinase inhibitors (TKIs). For patients diagnosed in the chronic phase, the 5-year survival rate now exceeds 90%, with some studies reporting rates over 95%. This significant improvement reflects the effectiveness of targeted therapies in achieving deep and durable molecular responses, transforming CML into a manageable chronic condition for most patients.
What foods are recommended for people with chronic myeloid leukemia?
For individuals with chronic myeloid leukemia (CML), a balanced, nutrient-dense diet is recommended to support overall health, maintain energy levels, and manage potential treatment side effects. This typically includes a variety of fruits, vegetables, whole grains, and lean proteins, while limiting processed foods, excessive sugars, and unhealthy fats. Adequate hydration is also crucial. Specific dietary modifications may be advised by healthcare providers based on individual treatment regimens and potential complications like nausea or mucositis.
What is the 20-year survival rate for patients with chronic myeloid leukemia (CML)?
The 20-year survival rate for patients with chronic myeloid leukemia (CML) has dramatically improved with the advent of tyrosine kinase inhibitors (TKIs). For patients diagnosed in the chronic phase and treated with TKIs, 20-year overall survival rates are now reported to be over 80%, a significant increase from the pre-TKI era.
How long does it take for CML to develop?
Chronic Myeloid Leukemia (CML) typically develops gradually over several years. The disease often begins in a chronic phase, which can last for 3 to 5 years or even longer, during which symptoms may be mild or absent. Without effective treatment, CML eventually progresses to an accelerated phase and then to a more aggressive blast crisis, which develops more rapidly.
What is the life expectancy for someone with chronic leukemia?
Life expectancy for individuals with chronic leukemia is highly variable, depending critically on the specific subtype, disease stage, genetic risk factors, and response to therapy. For example, many patients with chronic myeloid leukemia (CML) treated effectively with tyrosine kinase inhibitors can achieve a near-normal life expectancy. In contrast, chronic lymphocytic leukemia (CLL) prognoses range from decades of stable disease to more aggressive forms with shorter survival, while chronic myelomonocytic leukemia (CMML) generally carries a poorer prognosis.
Can you have CML for years and not know it?
Chronic Myeloid Leukemia (CML) frequently presents with an indolent chronic phase that can be asymptomatic or manifest with non-specific symptoms like fatigue or mild splenomegaly. This prolonged chronic phase can last for several years, making it possible for patients to live with undiagnosed CML for an extended period before incidental discovery or disease progression.
Can you live a long life with chronic myeloid leukemia?
The advent of tyrosine kinase inhibitors (TKIs) has profoundly transformed the prognosis for chronic myeloid leukemia (CML). Many patients now achieve deep molecular responses, leading to a near-normal life expectancy comparable to the general population. With consistent TKI therapy, CML is largely managed as a chronic condition, allowing for long-term survival for most individuals.
Contact Us
📍
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
✉️
For General Inquiry
info@pienomial.com
